FDA Clearance Tracker · K253818
Annalise Enterprise
Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 3, 2026
Substantially Equivalent
Time to decision
95 days
Received Nov 28, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K253818
- Device name
- Annalise Enterprise
- Applicant
- Harrison-AI Medical Pty, Ltd.
- Applicant location
- Sydney, AU
- Received
- Nov 28, 2025
- Decided
- Mar 3, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 892.2080
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QAS. The earliest in FDA's data is DEN170073, decided Feb 13, 2018.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for K253818
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Harrison-AI Medical Pty, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.